Anticoagulation and Inflammation Monitoring in Patients After Heart and Vascular Interventions

Launched by MEDICAL UNIVERSITY INNSBRUCK · Jan 15, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how to best monitor blood thinning treatment (called anticoagulation) in patients who have undergone heart or vascular surgery. The main focus is to find out which monitoring tool works best for a specific blood thinner called unfractionated heparin (UFH). Researchers will look at different methods of monitoring and see how they relate to problems like blood clots or bleeding after the surgery. They also want to understand how inflammation might be linked to confusion or delirium in these patients.

To be eligible for the trial, participants should be at least 17 years old and scheduled for heart or vascular surgery that requires anticoagulation. They must provide written consent to participate. During the study, participants can expect to undergo regular monitoring using various tests to track their anticoagulation levels and observe any potential complications. It’s important to know that this trial is currently recruiting participants and is open to all genders. Overall, this study aims to improve post-surgery care and outcomes for patients undergoing these types of interventions.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age: \> 17 years
• • Informed written consent
• • Scheduled for cardiac intervention where the use of UFH is expected (elective surgery)
• • Scheduled for vascular intervention when the need for perioperative anticoagulation is expected (elective surgery)
• • Patients receiving ECMO support
• Exclusion Criteria:
• • Patients that are known to be pregnant
• • Known participation in other interventional clinical trial